Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | RARB | P10826 | 4/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14877306 | 0.84 | CES2 (0.41) | KDM4ERARBPTPN1ALDH1A1HPGD | |
| SCHEMBL29359975 | 0.82 | KDM4E (0.68) | KDM4ERARBPTPN1ALDH1A1HPGD | |
| SCHEMBL18758 | 0.82 | KDM4E (0.68) | KDM4ERARBPTPN1ALDH1A1HPGD | |
| SCHEMBL6916181 | 0.82 | KDM4E (0.68) | KDM4ERARBPTPN1ALDH1A1HPGD | |
| SCHEMBL29594563 | 0.82 | KDM4E (0.68) | KDM4ERARBPTPN1ALDH1A1HPGD | |
| SCHEMBL688935 | 0.82 | KDM4E (0.50) | KDM4ERARBPTPN1ALDH1A1HPGD | |
| SCHEMBL3561878 | 0.82 | PLAU (0.54) | KDM4ERARBMEN1KMT2ACA1 | |
| Potassium SCHEMBL6268655 | 0.80 | KDM4E (0.65) | KDM4ERARBPTPN1ALDH1A1HPGD | |
| SCHEMBL9581206 | 0.80 | KDM4E (0.65) | KDM4ERARBPTPN1ALDH1A1HPGD | |
| SCHEMBL1886411 | 0.80 | KDM4E (0.65) | KDM4ERARBPTPN1ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 669 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043639-B2 | Polycationic methyl phospholipids for improved delivery of nucleic acids to eukaryotic cells | MOLECULAR TRANSFER, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| EP-4384508-A2 | LIPIDS FOR NUCLEIC ACID DELIVERY | Life Technologies Corporation (US) | 2024-06-19 | — | — | EP | disclosed |
| WO-2024031051-A1 | LIPIDS FOR NUCLEIC ACID DELIVERY | Life Technologies Corporation (US) | 2024-02-08 | — | — | WO | disclosed |
| WO-2024006937-A1 | LIPID COMPOSITIONS FOR IN VIVO DELIVERY | Life Technologies Corporation (US) | 2024-01-04 | — | — | WO | disclosed |
| US-20240000966-A1 | Lipid Compositions For In Vivo Delivery | Life Technologies Corporation | 2024-01-04 | — | — | US | disclosed |
| US-11850237-B2 | Compounds and methods for treating influenza | ROMARK LABORATORIES L.C. (US) | 2023-12-26 | — | — | US | disclosed |
| WO-2023018990-A2 | LIPIDS FOR NUCLEIC ACID DELIVERY | Life Technologies Corporation (US) | 2023-02-16 | — | — | WO | disclosed |
| EP-2445349-B1 | COMPOUNDS AND METHODS FOR TREATING INFLUENZA | ROMARK LABORATORIES LC (US) | 2022-02-09 | — | — | EP | disclosed |
| US-20210323984-A1 | POL YCATIONIC METHYL PHOSPHOLIPIDS FOR IMPROVED DELIVERY OF NUCLEIC ACIDS TO EUKARYOTIC CELLS | MOLECULAR TRANSFER, INC. | 2021-10-21 | — | — | US | disclosed |
| EP-3895706-A1 | THIAZOLINIDE COMPOUNDS FOR TREATING NON-INFLUENZA VIRAL INFECTIONS | Romark Laboratories, L.C. (US) | 2021-10-20 | — | — | EP | disclosed |
| EP-0558630-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1993-09-08 | — | — | EP | disclosed |
| EP-0558673-A1 | RETROVIRAL PROTEASE INHIBITORS. | MONSANTO CO (US) | 1993-09-08 | — | — | EP | disclosed |
| EP-0554400-A1 | RETROVIRAL PROTEASE INHIBITORS. | MONSANTO CO (US) | 1993-08-11 | — | — | EP | disclosed |
| US-5157041-A | Viricides | HOFFMANN-LA ROCHE INC. (US) | 1992-10-20 | — | — | US | disclosed |
| WO-1992008701-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
| WO-1992008700-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
| WO-1992008699-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
| WO-1992008698-A1 | RETROVIRAL PROTEASE INHIBITORS | MONSANTO COMPANY (US) | 1992-05-29 | — | — | WO | disclosed |
| EP-0432694-A2 | Aminoalcohols | F. HOFFMANN-LA ROCHE AG (CH) | 1991-06-19 | — | — | EP | disclosed |
| EP-0346847-A2 | Amino acid derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1989-12-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12043639-B2 | Polycationic methyl phospholipids for improved delivery of nucleic acids to eukaryotic cells | PHOSPHO1, MBOAT7, PLTP | KDM4E 1984/4885RARB 2309/4885PTPN1 4596/4885 |
| US-20240000966-A1 | Lipid Compositions For In Vivo Delivery | CHMP4B, LIPA, CETP | KDM4E 4151/4885RARB 3323/4885PTPN1 1891/4885 |
| US-11850237-B2 | Compounds and methods for treating influenza | HIF1AN, HAVCR2, NEU1 | KDM4E 2818/4885RARB 277/4885PTPN1 3721/4885 |
| US-20210323984-A1 | POL YCATIONIC METHYL PHOSPHOLIPIDS FOR IMPROVED DELIVERY OF NUCLEIC ACIDS TO EUKARYOTIC CELLS | POLRMT, PHOSPHO1, MBOAT7 | KDM4E 1333/4885RARB 3890/4885PTPN1 4411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.